Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Reports Second Quarter 2018 Financial Results
Completion of enrollment of Phase 3 DETECT Study of NexoBrid ®   Strategic discussions advancing with multiple parties Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel , Aug. 07, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company
View HTML
Toggle Summary MediWound to Host Second Quarter 2018 Financial Results Conference Call on August 7 at 8:30 a.m. Eastern Time
YAVNE, Israel , July 31, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second
View HTML
Toggle Summary MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.
Study fully funded by BARDA YAVNE, Israel , June 19, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its NexoBrid Phase 3
View HTML
Toggle Summary MediWound Completes Enrollment in NexoBrid® U.S. Phase 3 DETECT Study
Top-line acute data currently expected around year end 2018 YAVNE, Israel , June 11, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has
View HTML
Toggle Summary NexoBrid® Receives Marketing Authorization From South Korea’s Ministry of Health
Exclusive distributor BL&H Co., Ltd. plans commercial launch in second half of 2018 YAVNE, Israel , June 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management,
View HTML
Toggle Summary FDA Clears Development Pathway for NexoBrid® for Sulfur Mustard Injuries
YAVNE, Israel , May 29, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that following a meeting with the U.S.
View HTML
Toggle Summary MediWound Reports First Quarter 2018 Financial Results
Anticipates completion of enrollment of Phase 3 DETECT Study of NexoBrid ® around mid-2018 Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel , May 10, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies
View HTML
Toggle Summary MediWound to Host First Quarter 2018 Financial Results Conference Call on May 10 at 8:30 a.m. Eastern Time
YAVNE, Israel , May 04, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the first quarter
View HTML
Toggle Summary MediWound’s NexoBrid® to be Highlighted in Presentations at the American Burn Association 50th Annual Meeting Being Held on April 10-13, 2018 in Chicago
Presentations highlight European consensus around the efficacy and benefits of NexoBrid use in severe burns YAVNE, Israel , April 09, 2018 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe
View HTML
Toggle Summary MediWound Reports Fourth Quarter and Fiscal Year 2017 Financial Results
NexoBrid ® sales grow 60% in 2017 vs. 2016 Raised gross proceeds of $25.2 million through an equity offering to fund EscharEx ® clinical plan Awarded additional $32 million from BARDA bringing NexoBrid ® to be self-funded program Announces discussions regarding potential strategic transaction
View HTML